Results 41 to 50 of about 5,889,184 (390)

SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change [PDF]

Investigative and Clinical Urology, 2019
Purpose: Multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) and clear cell renal cell carcinoma with cystic change (MCRCC) have different prognoses despite similar histologic characteristics.
Sung Han Kim, Weon Seo Park, Jinsoo Chung   +2 more
doaj   +1 more source

Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial [PDF]

, 2016
BACKGROUND: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA ...
Barber, John R, De Marzo, Angelo M, Drake, Charles G, Goodman, Phyllis J, Gurel, Bora, Kristal, Alan R, Lippman, Scott M, Lucia, M. Scott, Murtola, Teemu J, Nelson, William G, Parnes, Howard L, Peskoe, Sarah B, Platz, Elizabeth A, Sutcliffe, Siobhan, Thompson, Ian M, Jr., Umbehr, Martin   +15 more
core   +2 more sources

Epidemiology of Prostate Cancer

World Journal of Oncology, 2019
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indolent course that may require only active surveillance ...
Prashanth Rawla
semanticscholar   +1 more source

Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria

JCO Global Oncology
PURPOSEThere is limited cancer clinical research in sub-Saharan African countries despite the significant burden of cancers. The primary objective of this strengths, weaknesses, opportunities, and threats (SWOT) analysis was to understand and document ...
Opeyemi Bolajoko, Parisa Fathi, Dottington Fulwood, Oluwaseyi Toye, Ademola Popoola, Hassan Dogo, Haruna Nggada, Chidiebere Ogo, Omolara Fatiregun, Mohammed Faruk, Lateef Abiodun, Anthonia Sowunmi, Catherine A. Oladoyinbo, Folakemi Odedina   +13 more
doaj   +1 more source

Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Nature Communications, 2019
The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
Hao Geng, Changhui Xue, Janet Mendonca, Xiao-Xin Sun, Qiong Liu, Patrick N. Reardon, Yingxiao Chen, Kendrick Qian, Vivian Hua, Alice Chen, Freddy Pan, Julia Yuan, Sang Dang, Tomasz M. Beer, Mu-Shui Dai, Sushant K. Kachhap, David Z. Qian   +16 more
doaj   +1 more source

Increasing the attractiveness of surgical disciplines for students: Implications of a robot-assisted hands-on training course for medical education

Frontiers in Surgery, 2022
BackgroundStructured implementation of robot-assisted surgery in the field of medical education is lacking. We assessed students' interest in robot-assisted surgery and tested if the implementation of a hands-on robotic course into the curriculum could ...
Jonas Ekrutt, Sami-Ramzi Leyh-Bannurah, Sophie Knipper, Frederik Schramm, Burkhard Beyer, Tobias Maurer, Tobias Maurer, Markus Graefen, Lars Budäus   +8 more
doaj   +1 more source

Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study [PDF]

Investigative and Clinical Urology, 2020
Purpose: This study aimed to compare progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) in Heng intermediate-risk patients with metastatic renal cell carcinoma (mRCC) treated with first-line immunotherapy (IT) or ...
Sung Han Kim , Dong-Eun Lee , Jae Young Joung , Ho Kyung Seo , Kang Hyun Lee , Jinsoo Chung   +5 more
doaj   +1 more source

How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer

Prostate Cancer and Prostatic Diseases, 2021
Advanced prostate cancer remains one of the most common and deadly cancers, despite advances in treatment options. Immunotherapy has provided little benefit to a majority of patients, largely due to the immunosuppressive tumor microenvironment that gives
J. Stultz, L. Fong
semanticscholar   +1 more source

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine

Genome Medicine, 2023
Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical trials do not include evolution as ...
Anssi Nurminen, Serafiina Jaatinen, Sinja Taavitsainen, Gunilla Högnäs, Tom Lesluyes, Naser Ansari-Pour, Teemu Tolonen, Kerstin Haase, Antti Koskenalho, Matti Kankainen, Juho Jasu, Hanna Rauhala, Jenni Kesäniemi, Tiia Nikupaavola, Paula Kujala, Irina Rinta-Kiikka, Jarno Riikonen, Antti Kaipia, Teemu Murtola, Teuvo L. Tammela, Tapio Visakorpi, Matti Nykter, David C. Wedge, Peter Van Loo, G. Steven Bova   +24 more
doaj   +1 more source

Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study [PDF]

, 2016
Introduction Current strategies for the management of prostate cancer are inadequate in Australia. We will, in this study, estimate current service needs and project the future needs for prostate cancer patients in Australia.
Clements, M. S., McHugh, B., O'Connell, D. L., Patel, M. I., Smith, D. P., Yu, X. Q.   +5 more
core   +1 more source